Background: The skepticism that implies that most
placebo-controlled studies are conducted by the
pharmaceutical industry and are not to be trusted is
pervasive. Published randomized controlled trials provide
a comprehensive picture of short-term efficacy and
tolerability in relation to placebo, but in the absence of realworld
clinical experience it is difficult to predict whether
the new drug has meaningful advantages or disadvantages
compared with existing agents.
Objectives: To present an experiential narrative account
of patients trialled on brexpiprazole as a part of patient
familiarization program (PFP) and early clinical experience.
Methods: Longitudinal follow-up patients initiated on
brexpiprazole with different clinical dimensions and
heterogeneity will be discussed.
Findings: Our experience suggest that brexpiprazole is
well tolerated, with a favorable safety profile that does
not exhibit significant rates of important adverse events
that can be seen with existing antipsychotics (akathisia,
sedation, weight gain or QTc prolongation), and therefore
may provide a useful treatment option for patients with
schizophrenia.conclusions: Clinical trial results add layers to
our knowledge and experience as clinicians. While
acknowledging the limitations of experiential descriptive,
it helps us reflect on the effectiveness of antipsychotics
under naturalistic clinical conditions; its results should
have particular applicability to clinical practice. At least,
experiential descriptive helps us to address the needs
of individual practitioners seeking to make good clinical
decisions for individual patients.